Skip to content

Revvity, Inc.

RVTY· NYSECore metricsCIK 31791

Laboratory analytical instruments24 peers

Last sale
Nov 12, 2026 · -0.78%
Market cap
$17.53B
111.64M shares
Filings
1,031
$728.90M
Q3 2026+3.7% FY25 yoy
$62.30M
Q3 2026−10.8% FY25 yoy
$95.14M
Q3 2026+2.9% FY25 yoy
$428.68M
Q3 2026derived−6.0% FY25 yoy
$0.56
Q3 2026−5.9% FY25 yoy
$592.80M
Q3 2026−20.9% FY25 yoy
$17.53B
69.2×
6.0×
2.4×
3.37%
0.18%

Twelve months to Oct 4, 2026 · derived

Price

$156.98+66.45%+$62.67past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.86BFY 2025
$3.83B0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-28$2,856,051,000reported
FY 20242024-12-29$2,755,026,000reported
FY 20232023-12-31$2,750,571,000reported
FY 20222023-01-01$3,311,822,000reported
FY 20212022-01-02$3,827,808,000 revisedreported
FY 20202021-01-03$2,663,230,000 revisedreported
FY 20192019-12-29$2,883,673,000reported
FY 20182018-12-30$2,777,996,000reported
FY 20172017-12-31$2,256,982,000reported
FY 20162017-01-01$2,115,517,000reported
FY 20152016-01-03$2,104,823,000 revisedreported
FY 20142014-12-28$2,237,219,000 revisedreported

Capital returns

Dividends and buybacks · FY2016 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025$32.80M$820.82M$853.62M$0.28111.80M sh−7.0%167.6%
FY2024$34.45M$369.58M$404.03M$0.28120.19M sh−2.7%74.6%
FY2023$34.97M$388.88M$423.85M$0.28123.53M sh−2.3%4279.6%
FY2022$35.34M$80.64M$115.98M$0.28126.41M sh+0.2%19.5%
FY2021$32.37M$73.07M$105.45M—126.18M sh+12.6%8.0%

Segments

Revenue by Segments, FY2018 to FY2025FY2018Diagnostics · FY2018 · $1.08BDiscovery & Analytical Solutions · FY2018 · $1.69BFY2019Diagnostics · FY2019 · $1.14BDiscovery & Analytical Solutions · FY2019 · $1.75BFY2020Diagnostics · FY2020 · $2.07BDiscovery & Analytical Solutions · FY2020 · $596.29MFY2021Diagnostics · FY2021 · $2.93BDiscovery & Analytical Solutions · FY2021 · $895.87MFY2022Diagnostics · FY2022 · $2.02BDiscovery & Analytical Solutions · FY2022 · $1.29BFY2023Life Sciences · FY2023 · $1.46BDiagnostics · FY2023 · $1.29BDiagnostics · FY2023 · $1.46BLife Sciences · FY2023 · $1.29BFY2024Life Sciences · FY2024 · $1.40BDiagnostics · FY2024 · $1.36BFY2025Life Sciences · FY2025 · $1.43BDiagnostics · FY2025 · $1.42B
LineFY2025ShareChange
Life Sciences$1.43B50%+2.3%
Diagnostics$1.42B50%+5.1%
Diagnostics———
Discovery & Analytical Solutions———
Life Sciences———
Total$2.86B

From the 10-K filed Feb 24, 2026RVTY

Laboratory analytical instruments

Revvity, Inc. is the 7th largest of the 25 covered companies the SEC files under this code, by revenue. SIC 3826

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Revvity, Inc. · CIK 31791 · Engraved from SEC EDGAR